FDA and CDC recommends resuming Johnson & Johnson vaccine

The FDA has recommended resuming the use of the Johnson & Johnson (Janssen) single-dose coronavirus vaccine following a pause to review it after a small number of patients in the U.S. developed a rare blood clot disorder after receiving it. 

All of the cases occurred in women between the ages of 18 and 59 and symptoms occurred six to 15 days after vaccination.

These reactions appear to be extremely rare, happening to a small percentage of people out of the 8 million who received the vaccine. The federal government and medical experts reviewed and analyzed the data before providing the recommendation that’s it’s safe to resume the vaccine and that any serious side effects are rare.

Currently, we are offering the two-dose vaccine made by Pfizer at our vaccination sites across Northeast Ohio. We monitor any reports of potential symptoms in our patients following a vaccine. The mRNA vaccines are not currently associated with any clotting disorder.

Visit our vaccine website for ongoing COVID-19 vaccine clinics in Ohio and Florida.

For Ohio caregiver, vendors and contractors, read about our regional vaccination locations.